CANY
FLGT icon

Caxton Associates (New York)’s Fulgent Genetics FLGT Stock Holding History

Caxton Associates (New York)’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$738K Buy
39,934
+28,502
+249% +$556K 0.02% 266
2024
Q3 		$248K Sell
11,432
-13,663
-54% -$305K 0.01% 464
2024
Q2 		$492K Buy
+25,095
New +$524K 0.02% 342
2024
Q1 		– Sell
-8,488
Closed -$245K – 495
2023
Q4 		$245K Buy
+8,488
New +$227K 0.01% 411
2022
Q1 		– Sell
-5,799
Closed -$583K – 579
2021
Q4 		$583K Buy
+5,799
New +$510K 0.06% 236
2021
Q2 		– Sell
-4,843
Closed -$468K – 508
2021
Q1 		$468K Buy
4,843
+762
+19% +$78.7K 0.04% 173
2020
Q4 		$213K Buy
+4,081
New +$171K 0.01% 106

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Caxton Associates (New York)'s FLGT Position: Q4 2024 in Review

Caxton Associates (New York) increased its Fulgent Genetics (FLGT) stake by 249% in Q4 2024, buying an estimated $556K and bringing the position to 39,934 shares worth $738K. The position accounts for 0.02% of the portfolio, ranked #266.

Caxton Associates (New York) first reported a position in FLGT in Q4 2020 and has held it in 7 quarters since. 189 funds tracked by Wall St. Rank hold FLGT as of Q4 2024.

  • Caxton Associates (New York) held 39,934 shares of Fulgent Genetics worth $738K as of Q4 2024.
  • Caxton Associates (New York) bought 28,502 Fulgent Genetics shares in Q4 2024, an estimated $556K.
  • Fulgent Genetics made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #266 holding.
  • Caxton Associates (New York) first reported a position in Fulgent Genetics in Q4 2020 and has held it in 7 quarters since.
  • 189 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.